The purpose of this study is to describe the genetic diversity of Hepatitis C virus (HCV) NS3/4a protease and NS5A protein of HCV in participants with chronic disease naive-drug or previously failed to double therapy (Peg-interferon and Ribavirin) and to identify the frequency of natural polymorphisms in HCV NS3/4a protease and NS5A protein that are associated with direct-acting antivirals (DAAs)-resistance.

This is a multicenter, observational/non-interventional, cross-sectional study to describe the genetic diversity of and to identify the natural polymorphisms in HCV NS3/4a protease and NS5A protein of hepatitis C virus in Brazilian participants with chronic HCV infection. Brazilian participants with Genotype 1 HCV infection treatment naive participants or previously failed to double therapy (Peg-interferon-α and Ribavirin) will be included in the trial and will constitute the trial population.

Inclusion Criteria:

• Participants mono infected with chronic Hepatitis C infection (genotype 1), including naive patients or previously failed to double therapy (Peg-interferon-α and Ribavirin)
• There is no restriction on fibrosis stage or clinical liver disease
• There is no restriction for comorbidities
• Male or female participants with age >=18 years

Exclusion Criteria:

• Participants failed to triple therapy using protease inhibitors
• Participants with co-infections (i.e. Human immunodeficiency virus, Hepatitis B virus)
• Participants that are not agree to sign the written informed consent
• Participants is taking part in an interventional clinical trial with an investigational agent (i.e. non-commercialized agent) or in an interventional clinical trial sponsored by Johnson & Johnson

Brazilian participants with Genotype 1 HCV infection treatment naive patients or previously failed to double therapy (Peg-interferon-α and Ribavirin) will be included in the trial.